Biological Products, (No Diagnostic Substances)
| Institution | Shares | Value | Ownership % | Change | Filing Date |
|---|---|---|---|---|---|
| BlackRock, Inc. | 47.10M | $16.57B | 8.73% | -295.7K | 2026-03-31 |
| VANGUARD CAPITAL MANAGEMENT LLC | 35.01M | $12.32B | 6.49% | -- | 2026-03-31 |
| STATE STREET CORP | 30.55M | $10.75B | 5.66% | -42.9K | 2026-03-31 |
| Capital World Investors | 29.29M | $10.30B | 5.43% | +6.19M | 2026-03-31 |
| MORGAN STANLEY | 15.84M | $5.57B | 2.93% | +91.5K | 2026-03-31 |
| GEODE CAPITAL MANAGEMENT, LLC | 15.43M | $5.41B | 2.86% | +1.13M | 2026-03-31 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 14.62M | $5.14B | 2.71% | -- | 2026-03-31 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 12.77M | $4.49B | 2.37% | +962.3K | 2026-03-31 |
| PRIMECAP MANAGEMENT CO/CA/ | 8.87M | $3.12B | 1.64% | -30.9K | 2026-03-31 |
| Capital International Investors | 7.12M | $2.50B | 1.32% | -11.06M | 2026-03-31 |
